Donna Reece

Donna Reece

UNVERIFIED PROFILE

Are you Donna Reece?   Register this Author

Register author
Donna Reece

Donna Reece

Publications by authors named "Donna Reece"

Are you Donna Reece?   Register this Author

100Publications

-Reads

Infusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From Experience.

J Oncol Pract 2018 Jul;14(7):425-426

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article
July 2018

Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.

Leukemia 2018 Apr 24. Epub 2018 Apr 24.

Dept. of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Canada.

View Article
April 2018

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.

Clin Lymphoma Myeloma Leuk 2018 Mar 5;18(3):225-234. Epub 2018 Jan 5.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

View Article
March 2018

Current Review on High-Risk Multiple Myeloma.

Curr Hematol Malig Rep 2017 04;12(2):96-108

Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada.

View Article
April 2017

Breaking bad…proteins.

Authors:
Donna E Reece

Blood 2017 04;129(15):2041-2042

PRINCESS MARGARET CANCER CENTRE.

View Article
April 2017

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.

J Hematol Oncol 2016 11 21;9(1):123. Epub 2016 Nov 21.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

View Article
November 2016

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.

Expert Opin Biol Ther 2016 10 17;16(10):1291-301. Epub 2016 Aug 17.

d Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article
October 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article
October 2016

The risk of secondary primary malignancies after therapy for multiple myeloma.

Leuk Lymphoma 2015 ;56(11):3012-21

a Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada.

View Article
September 2016

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.

Leuk Lymphoma 2015 24;56(9):2668-73. Epub 2015 Feb 24.

a Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada.

View Article
August 2016

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Blood 2016 08 23;128(5):732-5. Epub 2016 Jun 23.

Biology, University of New Brunswick, Saint John, NB, Canada; Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB, Canada.

View Article
August 2016

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2016 07 10;16(7):387-94. Epub 2016 May 10.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article
July 2016

Update on the initial therapy of multiple myeloma.

Authors:
Donna Reece

Am Soc Clin Oncol Educ Book 2013

From the Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article
November 2015

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.

J Oncol Pharm Pract 2015 Aug 29;21(4):285-92. Epub 2014 Apr 29.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON.

View Article
August 2015

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N Engl J Med 2015 Aug 2;373(7):621-31. Epub 2015 Jun 2.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).

View Article
August 2015

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.

Leuk Lymphoma 2015 Jan 27;56(1):232-5. Epub 2014 Jun 27.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Center , Toronto, ON , Canada.

View Article
January 2015

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.

Br J Haematol 2015 Jan 22;168(1):46-54. Epub 2014 Aug 22.

Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article
January 2015

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.

Oncologist 2013 29;18(5):611-8. Epub 2013 Apr 29.

Princess Margaret Hospital, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.

View Article
December 2013

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.

Mol Cancer Ther 2013 Nov 12;12(11):2331-41. Epub 2013 Sep 12.

Corresponding Author: Hong Chang, Toronto General Hospital, University Health Network, 200 Elizabeth Street, 11E-413, Toronto, ON M5G 2C4, Canada.

View Article
November 2013

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.

Br J Haematol 2013 Jun 18;161(6):802-10. Epub 2013 Apr 18.

Hematology, University of British Columbia, Vancouver, BC, Canada.

View Article
June 2013

Desensitization to lenalidomide in a patient with relapsed multiple myeloma.

Clin Lymphoma Myeloma Leuk 2013 Apr 26;13(2):162-5. Epub 2012 Oct 26.

Department of Pharmacy, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article
April 2013

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.

Leuk Lymphoma 2013 Mar 2;54(3):555-60. Epub 2013 Jan 2.

Princess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada.

View Article
March 2013

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Clin Lymphoma Myeloma Leuk 2013 Feb 27;13(1):25-31. Epub 2012 Oct 27.

Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article
February 2013

Carfilzomib in multiple myeloma: gold, silver, or bronze?

Authors:
Donna E Reece

Blood 2012 Oct;120(14):2776-7

Princess Margaret Hospital, Canada.

View Article
October 2012

Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.

Adv Hematol 2012 14;2012:621958. Epub 2012 Oct 14.

Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON, Canada M5G 2M9.

View Article
October 2012

Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.

Am J Hematol 2012 Aug 28;87(8):822-3. Epub 2012 May 28.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article
August 2012

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Hum Pathol 2012 Jun 1;43(6):858-64. Epub 2011 Nov 1.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

View Article
June 2012

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.

Biol Blood Marrow Transplant 2012 May 4;18(5):773-9. Epub 2011 Nov 4.

Princess Margaret Hospital, Division of Medical Oncology and Hematology, Toronto, ON, Canada.

View Article
May 2012

Posttransplantation maintenance therapy and optimal frontline therapy in myeloma.

Authors:
Donna E Reece

Hematology Am Soc Hematol Educ Program 2011 ;2011:197-204

Princess Margaret Hospital, Toronto, ON, Canada.

View Article
April 2012

Genomic stratification of multiple myeloma treated with novel agents.

Leuk Lymphoma 2012 Feb 19;53(2):202-7. Epub 2011 Sep 19.

Department of Laboratory Hematology and Medical Oncology, University Health Network, Toronto, Ontario, Canada.

View Article
February 2012

Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.

Biol Blood Marrow Transplant 2011 Dec 20;17(12):1790-5. Epub 2011 May 20.

Department of Laboratory Haematology, Department of Medical Oncology and Haematology, University Health Network, University of Toronto, Toronto, Canada.

View Article
December 2011

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

Cancer Chemother Pharmacol 2011 Jan 20;67(1):57-67. Epub 2010 Mar 20.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article
January 2011

Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.

Leuk Res 2011 Jan 26;35(1):95-8. Epub 2010 May 26.

Department of Laboratory Hematology, University Health Network, University of Toronto, Toronto, Canada.

View Article
January 2011

Development of target-specific treatments in multiple myeloma.

Br J Haematol 2010 Oct 7;151(1):3-15. Epub 2010 Jul 7.

Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

View Article
October 2010

CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Haematologica 2010 Sep 26;95(9):1542-7. Epub 2010 Apr 26.

Department of Laboratory Hematology, University Health Network, 200 Elizabeth Street, 11E-413 Toronto, ON, M5G 2C4.

View Article
September 2010

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Cancer Biol Ther 2010 Jun 27;9(11):936-44. Epub 2010 Jun 27.

Division of Molecular and Cellular Biology, Toronto General Hospital Research Institute and Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada.

View Article
June 2010

An update of the management of multiple myeloma: the changing landscape.

Authors:
Donna E Reece

Hematology Am Soc Hematol Educ Program 2005 :353-9

Princess Margaret Hospital, 610 University Ave., Ste. 5-207, Toronto, ON M5G 2M9, Canada.

View Article
November 2009

Recent trends in the management of newly diagnosed multiple myeloma.

Authors:
Donna E Reece

Curr Opin Hematol 2009 Jul;16(4):306-12

Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article
July 2009

Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.

Biol Blood Marrow Transplant 2009 Jun 9;15(6):686-93. Epub 2009 Apr 9.

Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale,AZ 85259, USA.

View Article
June 2009

Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.

Leuk Res 2009 Feb 3;33(2):259-62. Epub 2008 Aug 3.

Department of Laboratory Hematology, University Health Network, Toronto, Canada.

View Article
February 2009

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

J Clin Oncol 2008 Oct 21;26(29):4777-83. Epub 2008 Jul 21.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Suite 5-207, Toronto, Ontario, M5G 2M9 Canada.

View Article
October 2008

A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.

Cancer Treat Rev 2008 Aug 1;34(5):442-52. Epub 2008 Apr 1.

Keenan Research Centre, Li Ka Shing Knowledge Institute and Division of Hematology/Oncology, St. Michael's Hospital, 30 Bond Street, Room 2065Q, Toronto, ON, Canada M5B 1W8.

View Article
August 2008

Treatment of relapsed and refractory myeloma.

Leuk Lymphoma 2008 Aug;49(8):1470-85

Program for Multiple Myeloma and Related Diseases, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article
August 2008

Management of multiple myeloma: the changing landscape.

Authors:
Donna E Reece

Blood Rev 2007 Nov 29;21(6):301-14. Epub 2007 Aug 29.

Department of Medical Oncology/Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9.

View Article
November 2007

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.

Leuk Res 2007 Jun 22;31(6):779-82. Epub 2006 Sep 22.

Department of Laboratory Hematology, University Health Network, University of Toronto, Toronto, Canada.

View Article
June 2007

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

Clin Cancer Res 2007 Jan;13(2 Pt 1):621-9

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, 620 University Avenue, Toronto, Ontario, Canada.

View Article
January 2007

Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.

Br J Haematol 2006 Nov 22;135(4):486-91. Epub 2006 Sep 22.

Department of Laboratory Hematology, Toronto General Hospital, University Health Network, Toronto, Canada.

View Article
November 2006

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

J Clin Oncol 2005 Oct 29;23(28):7069-73. Epub 2005 Aug 29.

Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada.

View Article
October 2005

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Blood 2005 Apr 14;105(7):2941-8. Epub 2004 Dec 14.

Department of Medical Oncology, University Health Network, Princess Margaret Hospital and McLaughlin Centre of Molecular Medicine, University of Toronto, 620 University Ave, Rm 8-204, Toronto, ON, Canada M5G 2C1.

View Article
April 2005

IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.

Ann Hematol 2005 Feb 22;84(2):115-7. Epub 2004 Oct 22.

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada.

View Article
February 2005